PMID- 32734407
OWN - NLM
STAT- MEDLINE
DCOM- 20201030
LR  - 20220218
IS  - 1936-0541 (Electronic)
IS  - 1936-0533 (Print)
IS  - 1936-0533 (Linking)
VI  - 14
IP  - 5
DP  - 2020 Sep
TI  - Effect of COVID-19 on patients with compensated chronic liver diseases.
PG  - 701-710
LID - 10.1007/s12072-020-10058-6 [doi]
AB  - BACKGROUND AND AIM: Cytokine storm has been reported in patients with coronavirus 
      disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 
      (SARS-CoV-2) infection. We examine the incidence of acute on chronic liver 
      failure (ACLF) in COVID-19 patients with pre-existing compensated chronic liver 
      disease (CLD). METHODS: From 20 Jan 2020 to 7 Feb 2020, we studied 140 
      consecutive COVID-19 patients admitted to either Fuyang Second People's Hospital 
      (FYSPH), Anhui or the Fifth Medical Center of Chinese PLA General Hospital 
      (PLAGH) in Beijing, China. Pre-existing CLD includes those with liver cirrhosis 
      assessed by APRI/FIB-4 score and /or ultrasound; NAFLD as identified by either 
      ultrasound or hepatic steatosis index with significant liver fibrosis and chronic 
      hepatitis B (CHB) or hepatitis C (CHC) infection. The diagnosis, grading of 
      severity and clinical management of COVID-19 patients complied to the guideline 
      and clinical protocol issued by the China National Health Commission. All 
      patients had liver function test at least twice weekly till discharge with full 
      recovery or death. RESULTS: In total, 3 had liver cirrhosis, 6 patients had CHB, 
      13 had NAFLD with significant liver fibrosis (one also had CHB). On admission, 
      none had liver decompensation. COVID-19 disease progression was significantly 
      less frequent in non-CLD patients (10/118 8.5%) than CLD patients (13/22 59.1%, 
      p < 0.001). One patient with CLD had acute-on-chronic liver failure (ACLF). 
      CONCLUSION: Disease progression is significantly higher in those COVID-19 
      patients with CLD as compared to those with no CLD. ACLF can also occur in 
      patient with pre-existing compensated CLD who had severe COVID-19.
FAU - Ji, Dong
AU  - Ji D
AD  - The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, 
      China.
FAU - Zhang, Dawei
AU  - Zhang D
AD  - The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, 
      China.
FAU - Yang, Tieniu
AU  - Yang T
AD  - Fuyang Hospital of Anhui Medical University, Anhui, 236000, China.
FAU - Mu, Jinsong
AU  - Mu J
AD  - The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, 
      China.
FAU - Zhao, Peng
AU  - Zhao P
AD  - The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, 
      China.
FAU - Xu, Jing
AU  - Xu J
AD  - Fuyang Second People's Hospital, Anhui, 236000, China.
FAU - Li, Chen
AU  - Li C
AD  - The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, 
      China.
FAU - Cheng, Gregory
AU  - Cheng G
AD  - Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, 
      Hong Kong SAR, China.
FAU - Wang, Yudong
AU  - Wang Y
AD  - Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, 
      Hong Kong SAR, China.
FAU - Chen, Zhu
AU  - Chen Z
AD  - The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, 
      China. chenzhuren264@126.com.
FAU - Qin, Enqiang
AU  - Qin E
AD  - The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, 
      China. qeq2004@sina.com.
FAU - Lau, George
AU  - Lau G
AD  - The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, 100039, 
      China. gkklau@hnhmgl.com.
AD  - Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, 
      Hong Kong SAR, China. gkklau@hnhmgl.com.
LA  - eng
PT  - Journal Article
DEP - 20200730
PL  - United States
TA  - Hepatol Int
JT  - Hepatology international
JID - 101304009
SB  - IM
MH  - *Acute-On-Chronic Liver Failure/diagnosis/epidemiology/etiology
MH  - Betacoronavirus/isolation & purification
MH  - COVID-19
MH  - China/epidemiology
MH  - *Coronavirus Infections/epidemiology/therapy
MH  - Disease Progression
MH  - Female
MH  - *Hepatitis B, Chronic/complications/diagnosis
MH  - Humans
MH  - Incidence
MH  - Liver/diagnostic imaging
MH  - *Liver Cirrhosis/diagnosis/epidemiology/etiology
MH  - Liver Function Tests/methods
MH  - Male
MH  - Middle Aged
MH  - *Non-alcoholic Fatty Liver Disease/complications/diagnosis
MH  - *Pandemics
MH  - *Pneumonia, Viral/epidemiology/therapy
MH  - SARS-CoV-2
MH  - Ultrasonography/methods
PMC - PMC7391917
OTO - NOTNLM
OT  - Acute-on-chronic liver failure
OT  - COVID-19
OT  - Chronic liver diseases
COIS- Dong Ji, Dawei Zhang, Tieniu Yang, Jinsong Mu, Peng Zhao, Jing Xu, Chen Li, 
      Gregory Cheng, Yudong Wang, Zhu Chen, Enqiang Qin, George Lau declare that they 
      have no conflict of interest.
EDAT- 2020/08/01 06:00
MHDA- 2020/10/31 06:00
PMCR- 2020/07/30
CRDT- 2020/08/01 06:00
PHST- 2020/05/19 00:00 [received]
PHST- 2020/05/20 00:00 [accepted]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/10/31 06:00 [medline]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/07/30 00:00 [pmc-release]
AID - 10.1007/s12072-020-10058-6 [pii]
AID - 10058 [pii]
AID - 10.1007/s12072-020-10058-6 [doi]
PST - ppublish
SO  - Hepatol Int. 2020 Sep;14(5):701-710. doi: 10.1007/s12072-020-10058-6. Epub 2020 
      Jul 30.